S. Reyes

发表

Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity

E. R. James, S. Hoffman, C. Loucq, 2011, Science.

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

D. Carucci, D. Doolan, J. Bruder, 2011, PloS one.

Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity

S. Hoffman, D. Carucci, D. Freilich, 2016, Malaria Journal.

IMRAS—Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS

T. Richie, M. Sedegah, H. Ganeshan, 2021, PloS one.

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

S. Chaudhury, T. Richie, L. Garver, 2020, PloS one.

Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1

Bjoern Peters, S. Buus, Yohan Kim, 2013, Malaria Journal.

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

Sumana Chakravarty, Stephen L. Hoffman, S. Hoffman, 2010, Human vaccines.

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

S. Chaudhury, A. Lawrie, E. Bergmann-Leitner, 2021, PloS one.

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.

Sumana Chakravarty, Joana C. Silva, S. Hoffman, 2017, JCI insight.

Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Edward B. Miller, J. Bruder, T. Richie, 2013, Human vaccines & immunotherapeutics.

Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1

Bjoern Peters, S. Buus, Yohan Kim, 2013, Malaria Journal.

New World Monkey Aotus nancymae as a Model for Campylobacter jejuni Infection and Immunity

R. Meza, S. Walz, S. Reyes, 2006, Infection and Immunity.

Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection.

Andrea A. Berry, S. Hoffman, K. Lyke, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.